Addison Disease Clinical Trials and Treatments

Addison Disease results from destruction of 90% or more of the adrenal cortex, most commonly due to autoimmune adrenalitis (caused by autoantibodies against 21-hydroxylase enzyme). Less common causes include tuberculosis, fungal infections, metastatic cancer, adrenoleukodystrophy, and genetic disorders. Loss of cortisol production results in inability to maintain blood glucose, vascular tone, and stress response.

The most common symptoms of Addison Disease include Severe fatigue and weakness, Darkening of skin (hyperpigmentation), especially in creases and exposed areas, Low blood pressure and dizziness upon standing, Loss of appetite, nausea, and weight loss, Salt craving, among others. Approximately 39-60 cases per million people (higher in developed countries), with autoimmune cause accounting for 70-80% of cases. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Addison Disease from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. Research in Addison Disease focuses on understanding autoimmune mechanisms, improving androgen replacement (particularly DHEA), and optimizing glucocorticoid and mineralocorticoid replacement therapy. Trials investigating immunomodulatory approaches to prevent disease progression are emerging.

As of September 2026, Trial Friend's curated drug index does not include an FDA-approved treatment specific to Addison Disease. The Treatments section of this page checks FDA drug labels live and lists any approved drug whose label names the condition, and the trials listed below cover the investigational options.

The exact cause of Addison Disease is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. About 75% of primary adrenal insufficiency is autoimmune; no diagnostic gene test. Rare monogenic causes (autoimmune polyendocrine syndrome type 1, X-linked adrenoleukodystrophy) should be considered, especially in children and males. Approximately 39-60 cases per million people (higher in developed countries), with autoimmune cause accounting for 70-80% of cases. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Addison Disease. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. About 75% of primary adrenal insufficiency is autoimmune; no diagnostic gene test. Rare monogenic causes (autoimmune polyendocrine syndrome type 1, X-linked adrenoleukodystrophy) should be considered, especially in children and males.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Addison Disease clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Addison Disease clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.